Crohn's disease treatment has reached a peculiar inflection point — six drug classes with genuine efficacy, and yet a substantial proportion of patients cycle through them and still can't achieve deep remission. The question driving the most trial activity in 2026 isn't "does this drug work?" It's "which drug for which patient, at which point in their disease course?" The sequencing data emerging from head-to-head trials is going to reshape treatment algorithms that have been relatively static for years. That's the real story right now.
This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
Crohn's disease is a transmural inflammatory bowel disease affecting the entire gastrointestinal tract. Up to 40% of patients lose response to their first biologic within 12 months, and many never achieve endoscopic remission — the stringent endpoint that now defines treatment success in clinical trials. The 2026 research landscape is focused on a post-biologic-naïve world: selective IL-23 inhibitors (risankizumab, mirikizumab), the first oral advanced therapy for Crohn's (upadacitinib, approved 2023), combination biologic strategies for refractory disease, and microbiome-based approaches that remain scientifically compelling despite inconsistent trial results.
Risankizumab and the IL-23 Story
Risankizumab (Skyrizi, AbbVie) received FDA approval for moderate-to-severe Crohn's disease in June 2022 — and the data that got it there was genuinely impressive. In the Phase 3 ADVANCE and MOTIVATE induction trials, risankizumab achieved clinical remission (CDAI <150) in 45% and 42% of biologic-experienced patients respectively, versus 25% and 20% for placebo. Endoscopic response rates were even more striking: 40% vs. 12% in ADVANCE. The FORTIFY maintenance trial showed sustained endoscopic remission in 47% of responders at 52 weeks with 360 mg SC every 8 weeks.
What makes risankizumab mechanistically interesting is the specificity. IL-23 via its p19 subunit drives Th17 cell differentiation and sustains intestinal mucosal inflammation. Blocking only p19 — rather than both p19 and p40 as ustekinumab does — may offer a more targeted effect while preserving IL-12-mediated immune surveillance. Whether that translates to meaningfully different long-term safety is still an open question. Post-marketing studies running through 2026 are designed specifically to address it.
Upadacitinib: The First Oral Option After Biologic Failure
Upadacitinib (Rinvoq, AbbVie) received FDA approval for moderately to severely active Crohn's disease in June 2023 — the first oral advanced therapy approved for this indication. For patients who have failed multiple injections or infusions and face the prospect of indefinite parenteral treatment, that matters. An oral option that actually works in biologic-experienced disease changes the conversation.
The Phase 3 U-EXCEL (biologic-naïve) and U-EXCEED (biologic-experienced) trials showed clinical remission rates of 49.5% and 38.9% at week 12 induction with 45 mg daily — compared to 29.1% and 21.1% for placebo. Endoscopic response in biologic-experienced patients at week 12: 45.5% vs. 13.1%. U-ENDURE maintenance data showed 37% of responders maintained clinical remission at 52 weeks on 15 mg daily.
The safety profile carries the class warnings for JAK inhibitors — serious infection risk, thrombosis, cardiovascular events — and patient selection needs to account for these. Current recruiting trials are investigating upadacitinib as a first-line option before biologics, which would represent a significant sequencing shift if that data holds up.
Combination Biologic Therapy: The Refractory Disease Frontier
The VEGA trial in ulcerative colitis showed something that would have seemed reckless a decade ago: vedolizumab plus guselkumab outperformed either agent alone, with 83% clinical remission at week 12 in the combination arm versus 61% and 60% for monotherapy. That result opened the door to combination biologics in IBD, and the Crohn's field is now moving through it.
Several Phase 2 trials are recruiting patients who have failed two or more biologics, testing anti-TNF combined with anti-IL-23, or anti-integrin combined with JAK inhibitor. The theoretical rationale is sound: simultaneous blockade of complementary inflammatory pathways may prevent the compensatory upregulation that drives secondary loss of response to monotherapy. The historical concern — infection risk from dual immunosuppression — is being managed through careful safety monitoring with predefined stopping rules and frequent CBC and infection surveillance.
We don't yet know whether dual biologic therapy will become standard practice for refractory Crohn's. The data is preliminary, and the cost implications are substantial. But for patients who have genuinely exhausted monotherapy options, these trials represent something that doesn't exist outside of a research setting.
FMT and the Microbiome: More Complicated Than It Looked
FMT produces near-magical results in recurrent C. difficile — cure rates above 90%. The assumption that microbiome restoration might similarly benefit Crohn's disease seemed biologically reasonable. The data has been humbling. FMT trials in Crohn's have shown inconsistent results: some studies show modest benefit, others fail to beat placebo. Response appears heavily dependent on donor microbiome composition and disease phenotype in ways we don't fully understand yet.
Intensive protocols — multiple infusions over several weeks — have outperformed single-infusion approaches in small trials. Standardized pharmaceutical FMT products now approved for C. difficile are being tested in IBD under more controlled conditions. The 2026 microbiome trials worth watching are those using pre-treatment microbiome sequencing to select patients most likely to respond — essentially matching recipient to donor based on baseline dysbiosis profiles. Whether that selection approach materially improves outcomes remains to be demonstrated, but it's the right scientific question.
Who Qualifies for Crohn's Trials in 2026
Most Phase 2/3 Crohn's trials require confirmed diagnosis with endoscopic or histologic documentation, active disease at screening (CDAI 220–450, plus objective markers — CRP ≥5 mg/L or fecal calprotectin ≥250 µg/g or centrally read endoscopic evidence of active inflammation), and specific prior treatment history. Biologic-naïve and biologic-experienced populations are studied separately.
Standard pre-enrollment requirements include tuberculosis testing (IGRA or TST), hepatitis B serology, and for JAK inhibitor trials, cardiovascular risk assessment. Patients with stricturing or penetrating disease requiring surgery within the past three months are typically excluded. Having your current CDAI score, CRP, fecal calprotectin, and a copy of your most recent ileocolonoscopy report on hand significantly accelerates pre-screening at any trial site.
Key Takeaways
- Risankizumab (Skyrizi) achieved 45% clinical remission and 40% endoscopic response in Phase 3 ADVANCE — the endoscopic data is what distinguishes it from prior biologics in head-to-head context.
- Upadacitinib (Rinvoq) is the only oral advanced therapy approved for Crohn's. Phase 3 showed 38.9% clinical remission in biologic-experienced patients at week 12; trials are now investigating earlier use before biologics.
- Combination biologic trials (anti-TNF + vedolizumab, anti-TNF + anti-IL-23) are recruiting patients who have failed two or more biologics — offering access to approaches unavailable through standard care.
- FMT trials in Crohn's have inconsistent results; 2026 studies using pre-treatment microbiome sequencing for patient selection may finally clarify who benefits.
- For any Crohn's trial application, document CDAI score, current CRP and fecal calprotectin, complete biologic treatment history, and most recent endoscopy report — this dramatically speeds up pre-screening.
Best Biologics for Crohn's Disease 2026
Choosing the right biologic in 2026 depends on disease location, prior treatment history, and individual risk factors. The landscape has expanded considerably since infliximab alone defined the standard of care. Here's how the leading agents compare on factors that matter clinically:
| Drug (Class) | Mechanism | Approval Status | Best For |
|---|---|---|---|
| Risankizumab (Skyrizi) | Selective anti-IL-23 (p19) | FDA-approved June 2022 | Biologic-experienced; best endoscopic remission rates in class |
| Upadacitinib (Rinvoq) | JAK1 inhibitor (oral) | FDA-approved June 2023 | After biologic failure; only oral advanced therapy for CD |
| Ustekinumab (Stelara) | Anti-IL-12/23 (p40) | FDA-approved 2016 | Anti-TNF failure; favorable long-term safety record |
| Vedolizumab (Entyvio) | Anti-integrin α4β7 | FDA-approved 2014 | Gut-selective; preferred in elderly or infection-prone patients |
| Adalimumab / Infliximab | Anti-TNF | FDA-approved 2007 / 1998 | Biologic-naïve; fistulizing CD (infliximab); extensive safety data |
| Mirikizumab (Omvoh) | Selective anti-IL-23 (p19) | CD sNDA filing in progress (2025–2026) | Emerging; VIVID-1 Phase 3 showed 49.9% clinical remission at week 52 |
The sequencing question — risankizumab or upadacitinib as the preferred second-line agent after anti-TNF failure — is the central clinical controversy in Crohn's research right now. Direct comparative trials are underway. Until those data arrive, the choice turns on patient preference (oral vs. injectable), cardiovascular risk profile, and disease phenotype. Patients who have failed two or more biologics are uniquely positioned to enter sequencing or combination trials that offer options unavailable through standard care.
Finding Crohn's Trials in 2026
Search ClinicalMetric for "Crohn's disease" filtered to Phase 2/3, Recruiting. The Crohn's & Colitis Foundation's IBD Plexus patient registry is a direct pipeline to institutional trials. Academic IBD centers — University of Chicago, Mayo Clinic, Mount Sinai, UCSF — run trials that frequently aren't listed on ClinicalTrials.gov until they're already enrolling. Telling your gastroenterologist explicitly that you want to be considered for trial participation opens that door and should be a routine part of every IBD follow-up visit.